SCHEMBL5721746

SCHEMBL5721746

O=P(O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c2=NCN2C=CNC=32)[C@H](O)[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 6/20 0.52
P2RX2 Q9UBL9 4/20 0.51
RNASEL Q05823 3/20 0.50
P2RY1 P47900 5/20 0.49
P2RX4 Q99571 3/20 0.49
P2RX1 P51575 2/20 0.49
ENPP1 P22413 2/20 0.49
P2RY6 Q15077 2/20 0.49
GPR17 Q13304 2/20 0.49
P2RY11 Q96G91 1/20 0.49
P2RY2 P41231 4/20 0.49
SRC P12931 1/20 0.49
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
P2RY12 Q9H244 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919342 0.92 ATIC (0.49) P2RY1P2RY11P2RY2SRCSMN1; SMN2
SCHEMBL19458230 0.89 POLB (0.45) P2RX3P2RX2RNASELP2RY1P2RX1
SCHEMBL10769449 0.84 P2RX3 (0.53) P2RX3P2RX2RNASELP2RY1P2RX4
SCHEMBL11884609 0.83 P2RY2 (0.45) P2RX3P2RY2
SCHEMBL625829 0.81 P2RY1 (0.57) P2RX3P2RX2RNASELP2RY1P2RX4
SCHEMBL1429148 0.80 ADA (0.46) ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL5928106 0.80 ADA (0.45) ALDH1A1SMN1; SMN2
SCHEMBL11884671 0.77 ADA (0.34) ALDH1A1SMN1; SMN2
SCHEMBL8028076 0.76 P2RX3 (0.48) P2RX3P2RX2RNASELP2RY1P2RX4
SCHEMBL4377679 0.76 RNASEL (0.51) P2RX3P2RX2RNASELP2RY1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6703376-B2 ADMINISTERING TO THE AIRWAYS OF THE PATIENT A URIDINE PHOSPHATE SUCH AS URIDINE 5'TRIPHOSPHATE OR DI(URIDINE5') TETRAPHOSPHATE FOR PROMOTING DRAINAGE OF MUCOUS SECRETIONS IN THE CONGESTED AIRWAYS OF A BEDRIDDEN/IMMOBILIZED PATIENT INSPIRE PHARMACEUTICALS, INC. 2004-03-09 US claimed
US-20020155150-A1 USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS INSPIRE PHARMACEUTICALS, INC. 2002-10-24 US claimed
EP-0889728-B1 METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS INSPIRE PHARMACEUTICALS INC (US) 2006-08-09 EP disclosed
US-6703376-B2 ADMINISTERING TO THE AIRWAYS OF THE PATIENT A URIDINE PHOSPHATE SUCH AS URIDINE 5'TRIPHOSPHATE OR DI(URIDINE5') TETRAPHOSPHATE FOR PROMOTING DRAINAGE OF MUCOUS SECRETIONS IN THE CONGESTED AIRWAYS OF A BEDRIDDEN/IMMOBILIZED PATIENT INSPIRE PHARMACEUTICALS, INC. 2004-03-09 US disclosed
US-20020155150-A1 USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS INSPIRE PHARMACEUTICALS, INC. 2002-10-24 US disclosed
US-6420347-B1 Method of treating ciliary dyskinesia with uridine triphosphates and related compounds INSPIRE PHARMACEUTICALS, INC. 2002-07-16 US disclosed
EP-0938322-A2 USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS Inspire Pharmaceuticals, Inc. (US) 1999-09-01 EP disclosed
EP-0889728-A2 METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS Inspire Pharmaceuticals, Inc. (US) 1999-01-13 EP disclosed
US-5763447-A Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds INSPIRE PHARMACEUTICALS (US) 1998-06-09 US disclosed
WO-1997035591-A9 METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS 1998-02-19 WO disclosed
WO-1998003182-A2 USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS INSPIRE PHARMACEUTICALS, INC. (US) 1998-01-29 WO disclosed
WO-1997035591-A2 METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS INSPIRE PHARMACEUTICALS, INC. (US) 1997-10-02 WO disclosed
EP-0232967-B1 COMPETITIVE HOMOGENEOUS ASSAY AMOCO CORPORATION (US) 1993-04-28 EP disclosed
EP-0232967-A2 Competitive homogeneous Assay AMOCO CORPORATION (US) 1987-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020155150-A1 USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS UMPS, UPP1, P2RY1 P2RX3 18/4885P2RX2 52/4885RNASEL 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.